The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Geriatric assessment and management with a question prompt list using a web-based application to reduce treatment toxicity in older patients with cancer: A randomized controlled trial (J-SUPPORT 2101 study).
 
Ayumu Matsuoka
No Relationships to Disclose
 
Maiko Fujimori
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Daiichi-Sankyo; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
 
Atsuo Takashima
Honoraria - Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Amgen - Local PI (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Incyte; Kyowa Kirin International; Myriad Genetics; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Eisai; FUJIFILM Toyama Chemistry; Nihon Servier
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience; Eisai (Inst); Incyte; Syneos Health/Immunocore (Inst); Sysmex (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; BeiGene; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Beigene (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Yuta Maruki
No Relationships to Disclose
 
Akihiro Ohba
Honoraria - AstraZeneca; Eisai; Guardant Health; MSD; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Zymeworks
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Hidekazu Hirano
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Fujifilm; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Amgen (Inst); BeiGene (Inst); Bristol-Myers Squibb Japan (Inst); Taiho Pharmaceutical (Inst)
 
Keita Mori
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical
Consulting or Advisory Role - Welby
 
Tatsuo Akechi
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Igaku-Shoin; Janssen; Kowa; Kyowa Kirin International; Lundbeck; Meiji Seika Kaisha; Mochida Pharmaceutical Co. Ltd.; MSD; Nipro Corporation; Otsuka; Pfizer; Sumitomo Pharma Oncology; Takeda; Tsumura & Co.; Viatris
Patents, Royalties, Other Intellectual Property - The inventor of the pending patents (2020-135195, 2022-069057) (Institute) and the patents (7313617) (Institute) (Inst)
 
Yukari Tsubata
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Kyowa Kirin International; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Daiichi Sankyo (Inst); Ono Pharmaceutical (Inst)
 
Tomohiro Nishijima
Consulting or Advisory Role - Hisamitsu Pharmaceutical
 
Taichi Shimazu
No Relationships to Disclose
 
Tempei Miyaji
Leadership - Meaningful Outcome Consulting, Inc.
Stock and Other Ownership Interests - Meaningful Outcome Consulting, Inc.
Honoraria - AYUMI; Impute; Ono Pharmaceutical; Pfizer; Welby
 
Yoshiyuki Majima
No Relationships to Disclose
 
Takayo Sakiyama
No Relationships to Disclose
 
Kyoko Obama
No Relationships to Disclose
 
Fumio Nagashima
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Janssen; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Yosuke Uchitomi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Daiichi-Sankyo; Mitsubishi Tanabe Pharma; Sumitomo Pharma Oncology; Tsumura & Co.; Viatris pharma